Clinical Trial Phases

Trial Master File (TMF) Readiness in Phase 1: What to Include Early On

Posted on digi By digi

While often associated with large-scale Phase 3 trials, the Trial Master File (TMF) is just as critical during Phase 1. Regulatory agencies expect complete, current, and accessible documentation—even in early studies. The TMF tells the full story of a trial’s conduct, compliance, and oversight, and must be “inspection-ready at all times.” In this article, we explore what to include in your TMF from the earliest planning stages of a Phase 1 trial, who is responsible, and how to maintain quality and compliance throughout early development.
Click to read the full article.

Phase 1 (Safety and Dosage)

Using Real-World Evidence (RWE) Platforms to Streamline Phase 4 Studies

Posted on digi By digi

As Phase 4 trials move beyond the confines of tightly controlled environments, the ability to collect, analyze, and interpret real-world data (RWD) becomes central to post-marketing success. Real-World Evidence (RWE) platforms are digital tools and infrastructures designed to streamline this process—offering scalable, efficient, and regulatory-aligned support for generating insights into the long-term safety, effectiveness, and value of approved medicines.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Managing Placebo Use When Standard-of-Care Exists in Phase 2 Trials

Posted on digi By digi

Phase 2 trials are designed to evaluate the efficacy and safety of investigational treatments before proceeding to large-scale confirmatory trials. While placebo-controlled designs are the gold standard for assessing efficacy, their use becomes ethically complex when an effective standard-of-care (SoC) treatment already exists. This tutorial explores how to ethically and scientifically manage placebo use in Phase 2 studies while preserving both patient safety and trial integrity.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Pharmacoeconomic Evaluations Embedded in Phase 3 Trials: Building the Value Case Alongside Clinical Evidence

Posted on digi By digi

Pharmacoeconomic (PE) evaluation involves the analysis of cost versus benefit of a drug or intervention. These evaluations help determine whether a therapy delivers value for money in the context of limited healthcare resources. In Phase 3 trials, PE assessments are increasingly embedded to provide data that supports not just regulatory approval, but also reimbursement, pricing, and formulary inclusion.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Clinical Pharmacology Reviewer Expectations for Phase 1 Data

Posted on digi By digi

Phase 1 clinical studies form the backbone of early drug development. These studies not only establish safety and tolerability but also generate the essential clinical pharmacology data that regulatory reviewers rely on to evaluate future clinical plans. Whether filing an Investigational New Drug (IND) application or submitting a New Drug Application (NDA), understanding what clinical pharmacology reviewers expect helps ensure your data package is complete, compliant, and actionable. This guide outlines the key expectations from regulators like the FDA, EMA, and CDSCO for Phase 1 data submissions.
Click to read the full article.

Phase 1 (Safety and Dosage)

Comparative Effectiveness Research in Phase 4: Generating Real-World Value

Posted on digi By digi

Once a drug is approved and enters the real world, the next question stakeholders ask is: “How does this treatment compare to others already in use?” That’s the domain of Comparative Effectiveness Research (CER), a key objective in many Phase 4 clinical trials. Unlike earlier phases that test efficacy in controlled environments, Phase 4 CER evaluates how treatments perform in broader, more variable real-world settings—helping shape treatment guidelines, policy decisions, and reimbursement strategies.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Post-Trial Access and Continuation in Phase 2 Patients

Posted on digi By digi

As investigational drugs advance through development, questions about continued access for participants after a Phase 2 study ends become increasingly important. Post-trial access (PTA) refers to the provision of a study drug or its alternatives to participants after the trial concludes—especially when they have shown benefit or have no other therapeutic options. In Phase 2, where therapies are still unapproved and risks are evolving, managing PTA ethically, operationally, and regulatory-wise requires thoughtful planning. This tutorial covers best practices for offering continued access to patients after a Phase 2 trial, particularly in life-threatening or chronic conditions.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Bridging Studies as a Part of Phase 3 Programs: Regulatory Role, Design, and Global Development

Posted on digi By digi

A bridging study is a supplemental clinical study that provides data on the efficacy, safety, dosage, or pharmacokinetics (PK) of a drug in a specific population or region not fully represented in the original Phase 3 trials. Bridging studies are often requested by regulatory agencies in countries outside the original clinical trial regions to ensure that the treatment behaves similarly in their target populations.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Post-Marketing Commitments and Post-Authorization Safety Studies (PASS)

Posted on digi By digi

After a medicine enters the market, the need for safety monitoring intensifies—not fades. To ensure ongoing evaluation of benefit-risk balance, regulatory agencies may require pharmaceutical companies to undertake post-marketing commitments (PMCs) and conduct Post-Authorization Safety Studies (PASS). These studies are a central feature of Phase 4 pharmacovigilance strategy, especially for newly approved or high-risk drugs.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Early Termination of Phase 2 Trials: Criteria and Communication

Posted on digi By digi

Early termination of a Phase 2 trial—whether due to futility, safety concerns, or overwhelming efficacy—is a critical decision that can impact patients, sponsors, regulators, and future development plans. While stopping a study early may be necessary, it must be based on pre-established criteria, ethical principles, and transparent communication. This tutorial outlines how to plan for and implement early termination in Phase 2 clinical trials with scientific, regulatory, and operational rigor.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)